Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1784-1795
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1784
Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study
Yu-Feng Zhang, Guo-Dong Wang, Min-Guang Huang, Zhao-Qi Qiu, Jia Si, Mao-Yi Xu
Yu-Feng Zhang, Guo-Dong Wang, Min-Guang Huang, Zhao-Qi Qiu, Department of Oncology Radiotherapy, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji 311800, Zhejiang Province, China
Jia Si, Department of Electrocardiography, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji 311800, Zhejiang Province, China
Mao-Yi Xu, Department of Oncology, The First Hospital of Jiaxing (Affiliated Hospital of Jiaxing University), Jiaxing 314000, Zhejiang Province, China
Author contributions: Xu MY contributed to the study design and manuscript composition; Zhang YF and Si J helped to perform and check the statistical analysis; Qiu ZQ contributed to data collection and analysis; Wang GD and Huang MG contributed to proofreading and final approval of the article.
Supported by the Key Medical Disciplines Jointly Established by the Zhejiang Province and Jiaxing City: Oncology, No. 2023-SSGJ-001; and Jiaxing Key Laboratory of Tumor Radiotherapy, No. 2021-zlzdsys.
Institutional review board statement: The institutional review board of Affiliated Hospital of Jiaxing University approved this study (Approval No. 2023-LY-244).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Participants gave informed consent for data sharing.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mao-Yi Xu, MD, Doctor, Department of Oncology, The First Hospital of Jiaxing (Affiliated Hospital of Jiaxing University), No. 1882 South Central Road, Jiaxing 314000, Zhejiang Province, China. maoyixu1991@163.com
Received: June 15, 2023
Peer-review started: June 15, 2023
First decision: August 7, 2023
Revised: August 21, 2023
Accepted: September 18, 2023
Article in press: September 18, 2023
Published online: October 15, 2023
Processing time: 116 Days and 16.6 Hours
Core Tip

Core Tip: The Khorana risk score (KRS) has poor predictive value for cancer-associated thrombosis in a single tumor type but is associated with early all-cause mortality from cancer. In Japanese patients with gastric and colorectal cancer, the prechemotherapy baseline of KRS was independently associated with all-cause mortality within 2 years. The concept of time-sensitive management needs to be established for clinicians and community workers as well. The earlier the stratified intervention for patients with intermediate/high KRS, the more likely long-term survival benefit will be achieved.